Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and efficacy study of intranasal esketamine in treatment-resistant depression
RBR-5vkxtsPhase 3Recruiting
- Sponsor
- Ruschel Medicina e Pesquisa Clínica
- Start
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of esketamine in treatment-resistant depression (TRD) and major depressive disorder (MDD) (2 arms), sponsored by Ruschel Medicina e Pesquisa Clínica. Started Jul 2015; status: recruiting.
02
Drugs
esketamine
03
Conditions
treatment-resistant depression (TRD)major depressive disorder (MDD)
Beyond the preview
Go deeper on RBR-5vkxts.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-5vkxts.